NextCell Pharma (NXTCL) Stock Overview
A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
NXTCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NextCell Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.18 |
| 52 Week High | SEK 3.84 |
| 52 Week Low | SEK 0.69 |
| Beta | 0.14 |
| 1 Month Change | 0.85% |
| 3 Month Change | 9.46% |
| 1 Year Change | -10.61% |
| 3 Year Change | -81.24% |
| 5 Year Change | -93.79% |
| Change since IPO | -64.78% |
Recent News & Updates
Recent updates
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Mar 09
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate
Oct 07NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
May 23NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
Feb 01We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth
Sep 21Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation
May 31We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Feb 15Shareholder Returns
| NXTCL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.1% | 0.1% | -3.3% |
| 1Y | -10.6% | -9.5% | -3.4% |
Return vs Industry: NXTCL underperformed the Swedish Biotechs industry which returned -9.5% over the past year.
Return vs Market: NXTCL underperformed the Swedish Market which returned -3.4% over the past year.
Price Volatility
| NXTCL volatility | |
|---|---|
| NXTCL Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: NXTCL has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: NXTCL's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 24 | Mathias Svahn | www.nextcellpharma.com |
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
NextCell Pharma AB Fundamentals Summary
| NXTCL fundamental statistics | |
|---|---|
| Market cap | SEK 129.44m |
| Earnings (TTM) | -SEK 39.76m |
| Revenue (TTM) | SEK 10.24m |
Is NXTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTCL income statement (TTM) | |
|---|---|
| Revenue | SEK 10.24m |
| Cost of Revenue | SEK 14.29m |
| Gross Profit | -SEK 4.06m |
| Other Expenses | SEK 35.70m |
| Earnings | -SEK 39.76m |
Last Reported Earnings
May 31, 2025
Next Earnings Date
Oct 23, 2025
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -39.61% |
| Net Profit Margin | -388.33% |
| Debt/Equity Ratio | 0% |
How did NXTCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/03 18:49 |
| End of Day Share Price | 2025/09/03 00:00 |
| Earnings | 2025/05/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NextCell Pharma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Filip Einarsson | Redeye |